Akebia Therapeutics (AKBA) Stock Price, News & Analysis

Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $3.28 to $3.38
• 50-Day Range: $3.01 to $4.01
• 52-Week Range: $1.24 to $4.08
• Volume: 2.13 million shs
• Average Volume: 4.17 million shs
• Market Capitalization: $873.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.75
• Consensus Rating: Buy

Akebia Therapeutics Stock Analysis - MarketRank™

Akebia Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 201st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Akebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Akebia Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Akebia Therapeutics is -19.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Akebia Therapeutics is -19.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Akebia Therapeutics has a P/B Ratio of 29.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.57% of the outstanding shares of Akebia Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Akebia Therapeutics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Akebia Therapeutics has recently decreased by 0.51%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akebia Therapeutics does not currently pay a dividend.

Dividend Growth

Akebia Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.35

Percentage of Shares Shorted

9.57% of the outstanding shares of Akebia Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Akebia Therapeutics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Akebia Therapeutics has recently decreased by 0.51%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.53

News Sentiment

Akebia Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Akebia Therapeutics this week, compared to 4 articles on an average week.

Search Interest

15 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

4 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $258,841.00 in company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Akebia Therapeutics is held by insiders.

Percentage Held by Institutions

Only 33.92% of the stock of Akebia Therapeutics is held by institutions.

AKBA Stock Analysis - Frequently Asked Questions

How have AKBA shares performed this year?

Akebia Therapeutics' stock was trading at $1.90 at the beginning of the year. Since then, AKBA shares have increased by 72.9% and is now trading at $3.2850.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its earnings results on Thursday, May, 8th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.06. The biopharmaceutical company earned $57.34 million during the quarter, compared to the consensus estimate of $44.88 million.
Read the conference call transcript.

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' top institutional shareholders include Geode Capital Management LLC (2.31%), JPMorgan Chase & Co. (0.62%), Acadian Asset Management LLC (0.51%) and Connor Clark & Lunn Investment Management Ltd. (0.45%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, David A Spellman, Erik Ostrowski, Nicholas Grund and Richard C Malabre.
View institutional ownership trends.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and Exxon Mobil (XOM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AKBA
• CIK: 1517022
• Web: www.akebia.com
• Phone: (617) 871-2098
• Fax: 617-871-2099
• Employees: 430
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Akebia Therapeutics: $6.75
• High Price Target: $8.00
• Low Price Target: $6.00
• Potential Upside/Downside: +103.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.41 million
• Net Margins: -17.91%
• Pretax Margin: -17.91%
• Return on Equity: N/A
• Return on Assets: -13.47%

Debt

• Debt-to-Equity Ratio: 1.61
• Current Ratio: 1.98
• Quick Ratio: 1.84

Sales & Book Value

• Annual Sales: $203.73 million
• Price / Sales: 4.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 30.15

Miscellaneous

• Outstanding Shares: 265,145,000
• Free Float: 257,191,000
• Market Cap: $879.22 million
• Optionable: Optionable
• Beta: 0.96